Extracorporeal membrane oxygenation for severe acute respiratory failure.
Extracorporeal membrane oxygenation (ECMO) is a technique for providing life support, in case the natural lungs are failing and are not able to maintain a sufficient oxygenation of the body's organ systems. ECMO technique was an adaptation of conventional cardiopulmonary bypass techniques and introduced into treatment of severe acute respiratory distress syndrome (ARDS) in the 1970s. The initial reports of the use of ECMO in ARDS patients were quite enthusiastic, however, in the following years it became clear that ECMO was only of benefit in newborns with acute respiratory failure. In neonates treated with ECMO, survival rates of 80% could be achieved. In adult patients with ARDS, two large randomized controlled trials (RCTs) published in 1979 and 1994 failed to show an advantage of ECMO over conventional treatment; survival rates were only 10% and 33%, respectively, in the ECMO groups. Since then, ECMO technology as well as conventional treatment of adult ARDS have undergone further improvements. In conventional treatment lung-protective ventilation strategies were introduced and ECMO was made safer by applying heparin-coated equipment, membranes and tubings. Many ECMO centres now use these advanced ECMO technology and report survival rates in excess of 50% in uncontrolled data collections. The question, however, of whether the improved ECMO can really challenge the advanced conventional treatment of adult ARDS is unanswered and will need evaluation by a future RCT.
Lewandowski
K
K
Klinik für Anästhesiologie und operative Intensivmedizin, Charité, Campus Virchow-Klinikum, Berlin, Germany. klaus.lewandowski@charite.de
D000208:Acute Disease; D000328:Adult; D002648:Child; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D018579:Patient Selection; D011659:Pulmonary Gas Exchange; D016032:Randomized Controlled Trials as Topic; D012128:Respiratory Distress Syndrome / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D012127:Respiratory Distress Syndrome, Newborn / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D012131:Respiratory Insufficiency / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome